BPC September 02 update

​Corcept CORT +58% and Amarin AMRN -31% on respective court hearings

Price and Volume Movers

Corcept Therapeutics Incorporated (NASDAQ:CORT) shares closed up 58% to $19.87, with gains occurring during an ongoing court hearing regarding the validity of its patent for Korlym, according to a Bloomberg headline. Corcept has been in a battle with Teva for its patent for Korlym, a treatment for Cushing’s syndrome approved by the FDA in 2012.

Amarin Corporation plc (NASDAQ:AMRN) shares closed down 31% to $5.04, with its court appeal commencing today to review its patent for Vascepa against British generic drugmaker Hikma Pharmaceuticals.

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) announced a 1-for-10 reverse stock split became effective after hours today.

-

Major price movers (stocks priced > $1.00, volume > 50k):

Refer to the BioPharmCatalyst Biotech Stocks page for Top 10 Gainers/Losers/Unusual Volume:

ADVANCERS:

NanoViricides, Inc. (NNVC): $5.58; +42%.

Baudax Bio, Inc. (BXRX): $3.85; +27%.

Spring Bank Pharmaceuticals, Inc. (SBPH): $1.47; +19%.

CohBar, Inc. (CWBR): $1.12; +16%.

Repare Therapeutics Inc. (RPTX): $29.05; +16%.

DECLINERS:

Rexahn Pharmaceuticals, Inc. (REXN): $1.78; -18%.

ADiTx Therapeutics, Inc. (ADTX): $2.67; -16%.

AIM ImmunoTech Inc. (AIM): $2.03; -9%.

Atossa Therapeutics, Inc. (ATOS): $2.30; -8%.

Rockwell Medical, Inc. (RMTI): $1.23; -8%.

Pipeline updates below:

Pipeline Database Updates

Drug Stage Catalyst Market Cap

AGTC – Applied Genetic Technologies Corporation
AGTC-501
X-linked Retinitis Pigmentosa (XLRP)

Phase 1/2 Phase 1/2 12-month data due 4Q 2020.
$141.6 million

BCYC – Bicycle Therapeutics plc
BT1718
Solid tumors

Phase 2 Phase 2a initiation of dosing announced September 2, 2020.
$382.2 million

RCKT – Rocket Pharmaceuticals Inc.
RP-A501
Danon disease

Phase 1 Phase 1 data due 4Q 2020.
$1.4 billion

STRO – Sutro Biopharma Inc.
STRO-002
Ovarian and Endometrial Cancer

Phase 1 Phase 1 updated data September 9, 2020 noted ORR of 24% in 33 evaluable patients.
$425.5 million